UBS Upgrades Thermo Fisher with Bold 2027 Outlook | Durham News

UBS just gave Thermo Fisher Scientific a massive stock upgrade, jumping its price target from $540 to $730 — a nearly $200 leap — signaling a bold new outlook. The move isn’t based on recent earnings but on UBS’s bullish forecast for 2027: organic growth of 5-6%, expanding margins, and double-digit EPS growth fueled by pharma/biotech funding and R&D investment. Triggered by a new analyst taking over, this fresh perspective sees Thermo Fisher quietly outperforming — with Q2 revenue up 10% and EPS up 13% — and believes the company’s long-term potential is finally being recognized. If the pharma spending thaw holds, Thermo Fisher could close the valuation gap without needing any miracles. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/fb0154c8c2e64164